25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ALLR (Allarity) Stock Analysis
Buy, Hold or Sell?

Let's analyze Allarity together

I guess you are interested in Allarity Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Allarity’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Allarity’s Price Targets

I'm going to help you getting a better view of Allarity Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Allarity Therapeutics Inc

I send you an email if I find something interesting about Allarity Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Allarity (30 sec.)










1.2. What can you expect buying and holding a share of Allarity? (30 sec.)

How much money do you get?

How much money do you get?
$0.02
When do you have the money?
1 year
How often do you get paid?
20.5%

What is your share worth?

Current worth
$0.78
Expected worth in 1 year
$0.25
How sure are you?
46.2%

+ What do you gain per year?

Total Gains per Share
$-0.51
Return On Investment
-31.5%

For what price can you sell your share?

Current Price per Share
$1.63
Expected price per share
$1.23 - $2.255
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Allarity (5 min.)




Live pricePrice per Share (EOD)
$1.63
Intrinsic Value Per Share
$-12.47 - $-10.46
Total Value Per Share
$-11.69 - $-9.68

2.2. Growth of Allarity (5 min.)




Is Allarity growing?

Current yearPrevious yearGrowGrow %
How rich?$12.1m$1.8m$12m87.0%

How much money is Allarity making?

Current yearPrevious yearGrowGrow %
Making money-$6.1m-$3.1m-$2.9m-48.3%
Net Profit Margin-31,054.2%-1,242.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Allarity (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#545 / 853

Most Revenue
#682 / 853

Most Profit
#438 / 853

Most Efficient
#828 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Allarity?

Welcome investor! Allarity's management wants to use your money to grow the business. In return you get a share of Allarity.

First you should know what it really means to hold a share of Allarity. And how you can make/lose money.

Speculation

The Price per Share of Allarity is $1.63. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Allarity.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Allarity, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.78. Based on the TTM, the Book Value Change Per Share is $-0.13 per quarter. Based on the YOY, the Book Value Change Per Share is $0.34 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Allarity.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.15-9.2%-0.41-25.0%-0.21-13.0%-0.33-20.4%-0.76-46.8%-0.43-26.5%
Usd Book Value Change Per Share-0.46-27.9%-0.13-8.2%0.3420.9%0.021.2%0.021.5%0.010.6%
Usd Dividend Per Share0.000.0%0.000.3%0.000.2%0.052.8%0.032.0%0.021.0%
Usd Total Gains Per Share-0.46-27.9%-0.13-7.9%0.3421.1%0.074.1%0.063.5%0.031.7%
Usd Price Per Share1.01-1.31-0.45-1.39-1.52-0.78-
Price to Earnings Ratio-1.69--1.06--0.63--1.01--1.02--0.52-
Price-to-Total Gains Ratio-2.22--5.98-1.95--9.81--1.74--1.74-
Price to Book Ratio1.29-1.50--1.72--17.18--9.67--4.96-
Price-to-Total Gains Ratio-2.22--5.98-1.95--9.81--1.74--1.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.63
Number of shares613
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.03
Usd Book Value Change Per Share-0.130.02
Usd Total Gains Per Share-0.130.06
Gains per Quarter (613 shares)-78.5834.81
Gains per Year (613 shares)-314.31139.25
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
112-326-3248159129
224-653-638161117268
336-979-952242176407
449-1306-1266323234546
561-1632-1580404293685
673-1959-1894484351824
785-2285-2208565410963
897-2612-25226464681102
9109-2938-28367265271241
10122-3265-31508075851380

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.039.00.00.0%0.041.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%7.013.00.035.0%16.023.00.041.0%18.023.00.043.9%
Dividend per Share2.00.02.050.0%7.00.05.058.3%8.00.012.040.0%8.00.031.020.5%8.00.033.019.5%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%9.011.00.045.0%18.021.00.046.2%20.021.00.048.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Allarity Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.455-0.133-71%0.341-234%0.020-2388%0.024-2007%0.010-4452%
Book Value Per Share--0.7830.916-15%0.120+553%0.369+112%0.806-3%0.661+18%
Current Ratio--2.3112.445-5%0.638+262%1.149+101%1.106+109%3.177-27%
Debt To Asset Ratio--0.4260.410+4%1.093-61%0.814-48%0.622-31%0.426+0%
Debt To Equity Ratio--0.7430.706+5%0.139+433%1.188-37%0.992-25%0.7460%
Dividend Per Share---0.005-100%0.004-100%0.046-100%0.033-100%0.017-100%
Enterprise Value--24461754.21030483479.863-20%-3229814.210+113%17258891.424+42%24524897.5530%24524897.5530%
Eps---0.149-0.408+173%-0.211+42%-0.333+123%-0.763+411%-0.432+189%
Ev To Ebitda Ratio---2.664-1.696-36%-0.222-92%-1.508-43%-1.452-45%-1.452-45%
Free Cash Flow Per Share---0.353-0.281-20%-0.261-26%-0.250-29%-0.246-30%-0.151-57%
Free Cash Flow To Equity Per Share---0.5180.013-3969%0.314-265%0.055-1048%0.052-1090%0.028-1925%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---10.461----------
Intrinsic Value_10Y_min---12.469----------
Intrinsic Value_1Y_max---0.670----------
Intrinsic Value_1Y_min---1.049----------
Intrinsic Value_3Y_max---2.302----------
Intrinsic Value_3Y_min---3.345----------
Intrinsic Value_5Y_max---4.281----------
Intrinsic Value_5Y_min---5.833----------
Market Cap24579748.000+36%15698754.21019821979.863-21%6831435.790+130%21040891.424-25%22980073.165-32%11784652.905+33%
Net Profit Margin----310.5420%-12.4220%-107.6550%-64.5930%-33.9070%
Operating Margin----307.4170%-19.2500%-108.8890%-65.3330%-31.1070%
Operating Ratio---304.875-100%20.355-100%108.410-100%65.046-100%32.172-100%
Pb Ratio2.082+38%1.2901.499-14%-1.724+234%-17.184+1432%-9.667+849%-4.957+484%
Pe Ratio-2.730-61%-1.692-1.058-37%-0.625-63%-1.012-40%-1.019-40%-0.523-69%
Price Per Share1.630+38%1.0101.307-23%0.453+123%1.393-27%1.522-34%0.781+29%
Price To Free Cash Flow Ratio-1.156-61%-0.716-1.188+66%-0.660-8%-1.728+141%-1.535+114%-0.787+10%
Price To Total Gains Ratio-3.580-61%-2.219-5.978+169%1.953-214%-9.805+342%-1.735-22%-1.735-22%
Quick Ratio--2.1482.314-7%0.581+270%1.046+105%0.997+115%2.247-4%
Return On Assets---0.109-0.282+157%-0.230+110%-0.245+124%-0.196+79%-0.162+48%
Return On Equity---0.191-0.476+150%-0.021-89%-0.411+115%-0.358+88%-0.295+55%
Total Gains Per Share---0.455-0.128-72%0.345-232%0.066-789%0.057-902%0.027-1765%
Usd Book Value--12167000.00013902750.000-12%1808500.000+573%5598000.000+117%12173503.5500%12963713.256-6%
Usd Book Value Change Per Share---0.455-0.133-71%0.341-234%0.020-2388%0.024-2007%0.010-4452%
Usd Book Value Per Share--0.7830.916-15%0.120+553%0.369+112%0.806-3%0.661+18%
Usd Dividend Per Share---0.005-100%0.004-100%0.046-100%0.033-100%0.017-100%
Usd Enterprise Value--24461754.21030483479.863-20%-3229814.210+113%17258891.424+42%24524897.5530%24524897.5530%
Usd Eps---0.149-0.408+173%-0.211+42%-0.333+123%-0.763+411%-0.432+189%
Usd Free Cash Flow---5481000.000-4278500.000-22%-3937750.000-28%-3784666.667-31%-3713421.406-32%-2535119.871-54%
Usd Free Cash Flow Per Share---0.353-0.281-20%-0.261-26%-0.250-29%-0.246-30%-0.151-57%
Usd Free Cash Flow To Equity Per Share---0.5180.013-3969%0.314-265%0.055-1048%0.052-1090%0.028-1925%
Usd Market Cap24579748.000+36%15698754.21019821979.863-21%6831435.790+130%21040891.424-25%22980073.165-32%11784652.905+33%
Usd Price Per Share1.630+38%1.0101.307-23%0.453+123%1.393-27%1.522-34%0.781+29%
Usd Profit---2320000.000-6164250.000+166%-3186500.000+37%-4233250.000+82%-4381200.000+89%-3156425.122+36%
Usd Revenue---1500.000-100%56000.000-100%19166.667-100%11500.000-100%123755.503-100%
Usd Total Gains Per Share---0.455-0.128-72%0.345-232%0.066-789%0.057-902%0.027-1765%
 EOD+5 -3MRQTTM+10 -26YOY+18 -193Y+18 -195Y+12 -2510Y+13 -24

3.3 Fundamental Score

Let's check the fundamental score of Allarity Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.730
Price to Book Ratio (EOD)Between0-12.082
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.148
Current Ratio (MRQ)Greater than12.311
Debt to Asset Ratio (MRQ)Less than10.426
Debt to Equity Ratio (MRQ)Less than10.743
Return on Equity (MRQ)Greater than0.15-0.191
Return on Assets (MRQ)Greater than0.05-0.109
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Allarity Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.641
Ma 20Greater thanMa 501.467
Ma 50Greater thanMa 1001.198
Ma 100Greater thanMa 2001.092
OpenGreater thanClose1.650
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About Allarity Therapeutics Inc

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2025-08-22 03:44:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Allarity earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Allarity to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Allarity Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-31,054.2%+31,054.2%
TTM-31,054.2%YOY-1,242.2%-29,812.0%
TTM-31,054.2%5Y-6,459.3%-24,594.9%
5Y-6,459.3%10Y-3,390.7%-3,068.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--85.5%+85.5%
TTM-31,054.2%-168.0%-30,886.2%
YOY-1,242.2%-210.0%-1,032.2%
3Y-10,765.5%-289.9%-10,475.6%
5Y-6,459.3%-382.7%-6,076.6%
10Y-3,390.7%-520.3%-2,870.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Allarity is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Allarity to theΒ Biotechnology industry mean.
  • -10.9% Return on Assets means thatΒ Allarity generatedΒ $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Allarity Therapeutics Inc:

  • The MRQ is -10.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -28.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.9%TTM-28.2%+17.2%
TTM-28.2%YOY-23.0%-5.2%
TTM-28.2%5Y-19.6%-8.5%
5Y-19.6%10Y-16.2%-3.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.9%-11.9%+1.0%
TTM-28.2%-12.0%-16.2%
YOY-23.0%-11.3%-11.7%
3Y-24.5%-12.0%-12.5%
5Y-19.6%-11.7%-7.9%
10Y-16.2%-13.8%-2.4%
4.3.1.3. Return on Equity

Shows how efficient Allarity is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Allarity to theΒ Biotechnology industry mean.
  • -19.1% Return on Equity means Allarity generated $-0.19Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Allarity Therapeutics Inc:

  • The MRQ is -19.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -47.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.1%TTM-47.6%+28.6%
TTM-47.6%YOY-2.1%-45.6%
TTM-47.6%5Y-35.8%-11.8%
5Y-35.8%10Y-29.5%-6.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.1%-14.2%-4.9%
TTM-47.6%-15.1%-32.5%
YOY-2.1%-15.1%+13.0%
3Y-41.1%-16.9%-24.2%
5Y-35.8%-17.5%-18.3%
10Y-29.5%-19.7%-9.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Allarity Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Allarity is operatingΒ .

  • Measures how much profit Allarity makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Allarity to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Allarity Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-30,741.7%+30,741.7%
TTM-30,741.7%YOY-1,925.0%-28,816.7%
TTM-30,741.7%5Y-6,533.3%-24,208.3%
5Y-6,533.3%10Y-3,110.7%-3,422.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--154.1%+154.1%
TTM-30,741.7%-270.5%-30,471.2%
YOY-1,925.0%-254.3%-1,670.7%
3Y-10,888.9%-276.4%-10,612.5%
5Y-6,533.3%-350.8%-6,182.5%
10Y-3,110.7%-532.3%-2,578.4%
4.3.2.2. Operating Ratio

Measures how efficient Allarity is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Allarity Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM304.875-304.875
TTM304.875YOY20.355+284.520
TTM304.8755Y65.046+239.829
5Y65.04610Y32.172+32.874
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.891-1.891
TTM304.8752.917+301.958
YOY20.3553.080+17.275
3Y108.4103.835+104.575
5Y65.0464.924+60.122
10Y32.1726.864+25.308
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Allarity Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Allarity is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 2.31Β means the company has $2.31 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Allarity Therapeutics Inc:

  • The MRQ is 2.311. The company is able to pay all its short-term debts. +1
  • The TTM is 2.445. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.311TTM2.445-0.134
TTM2.445YOY0.638+1.807
TTM2.4455Y1.106+1.338
5Y1.10610Y3.177-2.070
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3113.480-1.169
TTM2.4453.795-1.350
YOY0.6384.104-3.466
3Y1.1494.607-3.458
5Y1.1065.762-4.656
10Y3.1776.164-2.987
4.4.3.2. Quick Ratio

Measures if Allarity is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Allarity to theΒ Biotechnology industry mean.
  • A Quick Ratio of 2.15Β means the company can pay off $2.15 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Allarity Therapeutics Inc:

  • The MRQ is 2.148. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.314. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.148TTM2.314-0.166
TTM2.314YOY0.581+1.733
TTM2.3145Y0.997+1.317
5Y0.99710Y2.247-1.250
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1482.952-0.804
TTM2.3143.302-0.988
YOY0.5813.927-3.346
3Y1.0464.393-3.347
5Y0.9975.875-4.878
10Y2.2476.549-4.302
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Allarity Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of AllarityΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Allarity to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.43Β means that Allarity assets areΒ financed with 42.6% credit (debt) and the remaining percentage (100% - 42.6%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Allarity Therapeutics Inc:

  • The MRQ is 0.426. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.410. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.426TTM0.410+0.016
TTM0.410YOY1.093-0.683
TTM0.4105Y0.622-0.212
5Y0.62210Y0.426+0.196
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4260.340+0.086
TTM0.4100.355+0.055
YOY1.0930.335+0.758
3Y0.8140.341+0.473
5Y0.6220.349+0.273
10Y0.4260.379+0.047
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Allarity is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Allarity to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 74.3% means that company has $0.74 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Allarity Therapeutics Inc:

  • The MRQ is 0.743. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.706. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.743TTM0.706+0.037
TTM0.706YOY0.139+0.567
TTM0.7065Y0.992-0.285
5Y0.99210Y0.746+0.246
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7430.393+0.350
TTM0.7060.436+0.270
YOY0.1390.436-0.297
3Y1.1880.461+0.727
5Y0.9920.459+0.533
10Y0.7460.514+0.232
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Allarity generates.

  • Above 15 is considered overpriced butΒ always compareΒ Allarity to theΒ Biotechnology industry mean.
  • A PE ratio of -1.69 means the investor is paying $-1.69Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Allarity Therapeutics Inc:

  • The EOD is -2.730. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.692. Based on the earnings, the company is expensive. -2
  • The TTM is -1.058. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.730MRQ-1.692-1.038
MRQ-1.692TTM-1.058-0.634
TTM-1.058YOY-0.625-0.432
TTM-1.0585Y-1.019-0.039
5Y-1.01910Y-0.523-0.496
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.730-2.537-0.193
MRQ-1.692-2.362+0.670
TTM-1.058-2.678+1.620
YOY-0.625-3.833+3.208
3Y-1.012-3.900+2.888
5Y-1.019-6.480+5.461
10Y-0.523-7.170+6.647
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Allarity Therapeutics Inc:

  • The EOD is -1.156. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.716. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.188. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.156MRQ-0.716-0.440
MRQ-0.716TTM-1.188+0.472
TTM-1.188YOY-0.660-0.528
TTM-1.1885Y-1.535+0.348
5Y-1.53510Y-0.787-0.748
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.156-3.385+2.229
MRQ-0.716-3.040+2.324
TTM-1.188-3.676+2.488
YOY-0.660-4.421+3.761
3Y-1.728-5.258+3.530
5Y-1.535-8.587+7.052
10Y-0.787-9.639+8.852
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Allarity is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.29 means the investor is paying $1.29Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Allarity Therapeutics Inc:

  • The EOD is 2.082. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.290. Based on the equity, the company is underpriced. +1
  • The TTM is 1.499. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.082MRQ1.290+0.792
MRQ1.290TTM1.499-0.209
TTM1.499YOY-1.724+3.222
TTM1.4995Y-9.667+11.166
5Y-9.66710Y-4.957-4.710
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0822.199-0.117
MRQ1.2901.995-0.705
TTM1.4992.190-0.691
YOY-1.7242.415-4.139
3Y-17.1842.574-19.758
5Y-9.6673.805-13.472
10Y-4.9574.462-9.419
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Allarity Therapeutics Inc.

4.8.1. Institutions holding Allarity Therapeutics Inc

Institutions are holding 1.949% of the shares of Allarity Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Geode Capital Management, LLC0.2249033921339210
2025-03-31Morgan Stanley - Brokerage Accounts0.1546023311233110
2025-03-31Corsair Capital Management LLC0.13260.004720000200000
2025-03-31Barclays PLC0.0668010078100780
2025-03-31Tower Research Capital LLC0.03120.0001470543910.2907
2025-06-30Citigroup Inc0.00980147214720
2025-03-31UBS Group AG0.00203003000
2025-03-31Bank of America Corp0.00030381672.7273
2025-03-31Advisor Group Holdings, Inc.00770
2025-03-31Goldman Sachs Group Inc000-20616-100
2025-03-31Stonepine Capital Management Llc000-67289-100
Total 0.62220.004893832+1639+1.7%

4.9.2. Funds holding Allarity Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr0.59550.000189801898010
2025-06-30Fidelity Extended Market Index0.17930.00012704500
2025-06-30Spartan Extended Market Index Pool F0.10090.000215209150519525.9494
2025-06-30Fidelity Series Total Market Index0.04460671800
2025-06-30Spartan Total Market Index Pool G0.01110167800
Total 0.93140.0004140451+104852+74.7%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets21,205
Total Liabilities9,038
Total Stockholder Equity12,167
 As reported
Total Liabilities 9,038
Total Stockholder Equity+ 12,167
Total Assets = 21,205

Assets

Total Assets21,205
Total Current Assets20,883
Long-term Assets322
Total Current Assets
Cash And Cash Equivalents 17,801
Net Receivables 1,609
Other Current Assets 1,473
Total Current Assets  (as reported)20,883
Total Current Assets  (calculated)20,883
+/-0
Long-term Assets
Property Plant Equipment 322
Long-term Assets  (as reported)322
Long-term Assets  (calculated)322
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities9,038
Long-term Liabilities0
Total Stockholder Equity12,167
Total Current Liabilities
Short-term Debt 1,375
Short Long Term Debt 1,375
Accounts payable 4,605
Other Current Liabilities 2,977
Total Current Liabilities  (as reported)9,038
Total Current Liabilities  (calculated)10,332
+/- 1,294
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock2
Retained Earnings -124,018
Accumulated Other Comprehensive Income -2,461
Other Stockholders Equity 138,644
Total Stockholder Equity (as reported)12,167
Total Stockholder Equity (calculated)12,167
+/-0
Other
Capital Stock2
Cash and Short Term Investments 17,801
Common Stock Shares Outstanding 15,543
Liabilities and Stockholders Equity 21,205
Net Debt -16,426
Net Invested Capital 13,542
Net Working Capital 11,845
Property Plant and Equipment Gross 322
Short Long Term Debt Total 1,375



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
> Total Assets 
1,357
5,946
5,403
5,450
4,646
5,799
5,226
6,536
7,380
13,013
11,882
2,093
12,994
37,456
38,591
38,077
39,591
37,575
27,201
25,040
26,067
27,054
33,403
27,453
38,780
36,987
49,633
31,290
23,194
18,134
14,544
12,702
13,426
13,875
11,862
11,969
30,883
20,378
22,650
29,730
21,205
21,20529,73022,65020,37830,88311,96911,86213,87513,42612,70214,54418,13423,19431,29049,63336,98738,78027,45333,40327,05426,06725,04027,20137,57539,59138,07738,59137,45612,9942,09311,88213,0137,3806,5365,2265,7994,6465,4505,4035,9461,357
   > Total Current Assets 
1,282
3,402
2,889
2,941
2,100
3,435
2,808
4,366
4,555
8,895
6,915
1,306
7,608
5,461
2,210
1,993
2,989
2,538
3,349
1,602
1,635
1,328
1,715
2,028
8,497
7,635
21,054
17,211
10,119
6,061
4,968
2,966
3,686
4,387
1,971
2,295
21,309
20,366
22,341
29,422
20,883
20,88329,42222,34120,36621,3092,2951,9714,3873,6862,9664,9686,06110,11917,21121,0547,6358,4972,0281,7151,3281,6351,6023,3492,5382,9891,9932,2105,4617,6081,3066,9158,8954,5554,3662,8083,4352,1002,9412,8893,4021,282
       Cash And Cash Equivalents 
1,282
1,012
2,824
1,988
1,347
2,457
1,373
2,072
2,178
4,452
2,337
536
4,811
1,360
237
438
1,189
331
1,528
1
392
30
298
105
6,598
5,584
19,555
14,544
7,639
3,946
2,029
295
420
1,399
166
312
19,233
18,463
19,533
25,201
17,801
17,80125,20119,53318,46319,2333121661,3994202952,0293,9467,63914,54419,5555,5846,5981052983039211,5283311,1894382371,3604,8115362,3374,4522,1782,0721,3732,4571,3471,9882,8241,0121,282
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
350
0
0
0
0
0
0
0
0
0
0
72
0
0
00720000000000350000000000000000000000000000
       Net Receivables 
0
0
65
93
3
0
0
2
0
1,367
4
408
461
0
0
0
33
32
96
22
0
0
1,124
10,191
1,762
1,806
1,345
1,297
1,432
1,488
871
1,333
1,603
1,632
946
1,331
1,579
1,652
2,229
1,115
1,609
1,6091,1152,2291,6521,5791,3319461,6321,6031,3338711,4881,4321,2971,3451,8061,76210,1911,124002296323300046140841,36702003936500
       Other Current Assets 
0
2,390
0
860
750
978
1,435
2,257
2,342
1,529
2,904
193
1,073
2,897
1,972
1,555
1,768
2,176
1,725
1,579
1,243
1,298
293
1,923
137
245
65
1,249
83
627
2,068
1,338
359
1,356
859
652
497
251
579
3,106
1,473
1,4733,1065792514976528591,3563591,3382,068627831,249652451371,9232931,2981,2431,5791,7252,1761,7681,5551,9722,8971,0731932,9041,5292,3422,2571,43597875086002,3900
   > Long-term Assets 
76
2,544
2,514
2,509
2,545
2,364
2,417
2,170
2,824
4,117
4,967
787
5,386
31,995
36,381
36,085
36,602
35,036
23,853
23,438
24,432
25,725
31,688
25,425
30,283
29,352
28,579
14,079
13,112
12,073
9,576
9,736
9,740
9,488
9,891
9,674
9,574
12
309
308
322
322308309129,5749,6749,8919,4889,7409,7369,57612,07313,11214,07928,57929,35230,28325,42531,68825,72524,43223,43823,85335,03636,60236,08536,38131,9955,3867874,9674,1172,8242,1702,4172,3642,5452,5092,5142,54476
       Property Plant Equipment 
76
73
69
0
0
4
7
69
79
65
61
22
56
58
56
525
506
454
438
401
379
368
352
165
141
117
94
71
47
46
27
25
26
29
20
18
17
12
309
308
322
32230830912171820292625274647719411714116535236837940143845450652556585622616579697400697376
       Goodwill 
0
0
0
2,309
2,342
2,179
2,092
1,915
1,889
1,946
2,013
0
1,783
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000001,78302,0131,9461,8891,9152,0922,1792,3422,309000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
845
0
0
491
350
314
254
0
0
0
0
0
0
0
0
0
0
0
0
000000000000254314350491008450000000000000000000000
       Intangible Assets 
0
2,471
2,445
200
203
181
178
159
771
2,074
2,861
0
3,513
31,937
36,325
35,560
36,096
34,582
23,415
23,037
23,495
24,529
30,491
24,562
0
28,744
28,135
13,694
12,811
12,027
9,549
9,711
9,714
9,459
9,871
9,656
9,557
0
0
0
0
00009,5579,6569,8719,4599,7149,7119,54912,02712,81113,69428,13528,744024,56230,49124,52923,49523,03723,41534,58236,09635,56036,32531,9373,51302,8612,0747711591781812032002,4452,4710
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,266
0
0
0
0
0
0
0
0
000000003,26600000000000000000000000000000000
> Total Liabilities 
13
293
291
518
363
71
513
1,336
901
1,329
1,344
1,699
4,099
10,555
10,686
12,780
11,730
14,096
5,985
5,239
4,370
4,074
6,552
5,807
9,960
4,219
31,481
14,416
14,991
14,631
12,654
13,041
14,149
17,254
14,613
18,440
11,048
7,414
10,839
11,061
9,038
9,03811,06110,8397,41411,04818,44014,61317,25414,14913,04112,65414,63114,99114,41631,4814,2199,9605,8076,5524,0744,3705,2395,98514,09611,73012,78010,68610,5554,0991,6991,3441,3299011,3365137136351829129313
   > Total Current Liabilities 
13
293
291
518
363
71
513
1,336
901
1,329
1,344
1,699
4,099
5,512
5,433
7,229
6,123
8,744
4,728
4,026
3,157
2,833
5,533
5,721
4,335
3,838
20,719
12,711
11,462
12,955
11,222
11,588
12,668
15,744
14,167
18,008
10,616
7,414
10,839
11,061
9,038
9,03811,06110,8397,41410,61618,00814,16715,74412,66811,58811,22212,95511,46212,71120,7193,8384,3355,7215,5332,8333,1574,0264,7288,7446,1237,2295,4335,5124,0991,6991,3441,3299011,3365137136351829129313
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
1,448
2,899
5,350
3,419
5,575
623
91
769
211
1,520
1,815
156
196
0
164
0
58
2,652
2,687
350
0
1,300
2,690
1,325
1,337
1,350
1,363
1,375
1,3751,3631,3501,3371,3252,6901,30003502,6872,65258016401961561,8151,520211769916235,5753,4195,3502,8991,4480000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,411
0
0
0
0
0
0
0
2,644
2,687
350
0
1,300
2,690
1,325
1,337
1,350
1,363
1,375
1,3751,3631,3501,3371,3252,6901,30003502,6872,64400000001,4110000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
1,274
901
1,329
1,139
472
0
1,158
1,942
1,297
2,215
2,451
2,182
1,789
1,706
1,785
2,116
2,129
14,191
739
698
5,799
5,555
4,707
6,251
6,449
8,089
6,347
8,416
11,058
7,753
4,693
4,182
4,347
4,605
4,6054,3474,1824,6937,75311,0588,4166,3478,0896,4496,2514,7075,5555,79969873914,1912,1292,1161,7851,7061,7892,1822,4512,2151,2971,9421,15804721,1391,3299011,2740000000
       Other Current Liabilities 
13
293
291
518
363
71
513
63
0
0
205
1,226
4,099
2,906
592
582
489
719
1,923
2,147
681
837
1,840
1,776
4,123
2,849
11,333
6,696
4,424
8,107
2,278
2,416
4,193
9,369
4,392
4,217
1,481
1,324
5,233
5,275
2,977
2,9775,2755,2331,3241,4814,2174,3929,3694,1932,4162,2788,1074,4246,69611,3332,8494,1231,7761,8408376812,1471,9237194895825922,9064,0991,22620500635137136351829129313
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
5,043
5,253
5,551
5,607
5,352
1,256
1,213
1,213
1,241
1,019
86
5,625
381
10,762
1,705
3,800
1,676
1,432
1,453
1,481
1,510
446
432
432
0
0
0
0
00004324324461,5101,4811,4531,4321,6763,8001,70510,7623815,625861,0191,2411,2131,2131,2565,3525,6075,5515,2535,0430000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,003
0
0
0
0
0
0
0
0
0
0
00000000002,003000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,142
700
656
619
349
0
343
0
0
0
0
0
0
0
0
0000000034303496196567009,14200000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,432
0
0
0
0
0
0
0
0
0
0
00000000001,432000000000000000000000000000000
> Total Stockholder Equity
1,345
5,652
5,112
4,932
4,282
5,728
4,713
5,200
6,345
11,467
10,538
394
8,754
26,574
23,807
21,357
24,370
20,223
18,594
17,219
21,191
22,980
26,851
21,646
28,820
32,768
18,152
16,874
8,203
3,503
1,890
-339
-723
-3,379
-2,751
-6,471
19,835
12,964
11,811
18,669
12,167
12,16718,66911,81112,96419,835-6,471-2,751-3,379-723-3391,8903,5038,20316,87418,15232,76828,82021,64626,85122,98021,19117,21918,59420,22324,37021,35723,80726,5748,75439410,53811,4676,3455,2004,7135,7284,2824,9325,1125,6521,345
   Common Stock
70
74
121
120
125
154
152
155
157
181
187
196
232
391
386
378
537
516
911
965
1,276
1,522
1,624
1,886
2,851
3,157
810
885
1
1
2
0
-5,637
0
0
0
3
0
1
2
2
22103000-5,63702118858103,1572,8511,8861,6241,5221,2769659115165373783863912321961871811571551521541251201217470
   Retained Earnings -124,018-121,698-118,966-111,513-99,923-98,294-94,451-92,729-88,282-85,902-82,550-79,712-74,675-69,572-66,492-43,418-45,090-43,515-37,432-37,655-33,355-30,594-28,968-17,643-15,121-11,137-9,366-6,986-13,125-7,078-1,448-5,421-7,0930-3,012-2,286-1,554-669-539-107-114
   Accumulated Other Comprehensive Income 
1,388
48
0
0
0
0
-192
-4,303
2,481
1,443
0
-13
1,458
-277
19
28
26
29
36
26
42
74
1,375
61
3,126
-419
0
-814
0
-1,871
-721
-637
-666
-758
-411
-386
-530
-693
-354
-630
-2,461
-2,461-630-354-693-530-386-411-758-666-637-721-1,8710-8140-4193,126611,3757442263629262819-2771,458-1301,4432,481-4,303-1920000481,388
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
83,156
0
0
0
0
0
0
0
0
0
0
000000000083,156000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000
   Other Stockholders Equity 
0
5,638
5,530
5,481
5,711
7,860
7,765
9,348
10,799
15,265
11,800
7,288
20,190
33,446
32,769
32,087
38,928
37,321
46,616
46,822
53,229
59,039
64,894
63,214
67,933
73,448
-600
84,233
-1,228
83,029
83,158
83,437
82,588
88,366
90,369
90,699
120,285
125,170
131,130
140,995
138,644
138,644140,995131,130125,170120,28590,69990,36988,36682,58883,43783,15883,029-1,22884,233-60073,44867,93363,21464,89459,03953,22946,82246,61637,32138,92832,08732,76933,44620,1907,28811,80015,26510,7999,3487,7657,8605,7115,4815,5305,6380



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-9
Gross Profit-9-9
 
Operating Income (+$)
Gross Profit-9
Operating Expense-18,329
Operating Income-27,241-18,338
 
Operating Expense (+$)
Research Development6,096
Selling General Administrative11,442
Selling And Marketing Expenses0
Operating Expense18,32917,538
 
Net Interest Income (+$)
Interest Income533
Interest Expense--653
Other Finance Cost-1,306
Net Interest Income-120
 
Pretax Income (+$)
Operating Income-27,241
Net Interest Income-120
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-24,896-29,586
EBIT - interestExpense = -24,896
-24,896
-25,168
Interest Expense-653
Earnings Before Interest and Taxes (EBIT)-25,549-25,549
Earnings Before Interest and Taxes (EBITDA)-27,241
 
After tax Income (+$)
Income Before Tax-24,896
Tax Provision--381
Net Income From Continuing Ops-24,515-24,515
Net Income-24,515
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses27,241
Total Other Income/Expenses Net2,345120
 

Technical Analysis of Allarity
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Allarity. The general trend of Allarity is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Allarity's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Allarity Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Allarity Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.99 < 2.06 < 2.255.

The bearish price targets are: 1.24 > 1.23 > 1.23.

Know someone who trades $ALLR? Share this with them.πŸ‘‡

Allarity Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Allarity Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Allarity Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Allarity Therapeutics Inc. The current macd is 0.19595871.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Allarity price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Allarity. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Allarity price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Allarity Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAllarity Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Allarity Therapeutics Inc. The current adx is 50.89.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Allarity shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Allarity Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Allarity Therapeutics Inc. The current sar is 1.18877619.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Allarity Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Allarity Therapeutics Inc. The current rsi is 57.64. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Allarity Therapeutics Inc Daily Relative Strength Index (RSI) ChartAllarity Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Allarity Therapeutics Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Allarity price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Allarity Therapeutics Inc Daily Stochastic Oscillator ChartAllarity Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Allarity Therapeutics Inc. The current cci is 27.66.

Allarity Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAllarity Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Allarity Therapeutics Inc. The current cmo is 5.67364866.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Allarity Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAllarity Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Allarity Therapeutics Inc. The current willr is -72.58064516.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Allarity is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Allarity Therapeutics Inc Daily Williams %R ChartAllarity Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Allarity Therapeutics Inc.

Allarity Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Allarity Therapeutics Inc. The current atr is 0.17750721.

Allarity Therapeutics Inc Daily Average True Range (ATR) ChartAllarity Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Allarity Therapeutics Inc. The current obv is 448,183,357.

Allarity Therapeutics Inc Daily On-Balance Volume (OBV) ChartAllarity Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Allarity Therapeutics Inc. The current mfi is 95.41.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Allarity Therapeutics Inc Daily Money Flow Index (MFI) ChartAllarity Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Allarity Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-30MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-24STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-03BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Allarity Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Allarity Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.641
Ma 20Greater thanMa 501.467
Ma 50Greater thanMa 1001.198
Ma 100Greater thanMa 2001.092
OpenGreater thanClose1.650
Total5/5 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Allarity with someone you think should read this too:
  • Are you bullish or bearish on Allarity? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Allarity? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Allarity Therapeutics Inc

I send you an email if I find something interesting about Allarity Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Allarity Therapeutics Inc.

Receive notifications about Allarity Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.